Percutaneous coronary intervention for left main stem disease: Impact of diabetes mellitus on mortality by Bawamia BR et al.
OR I G I N A L S T UD I E S
Percutaneous coronary intervention for left main stem disease:
Impact of diabetes mellitus on mortality
Bilal R. Bawamia MRCP1 | Mohaned Egred FRCP2,3 | Matthew Jackson MRCP1 |
Ian Purcell FRCP2 | David Austin FRCP1 | Azfar G. Zaman FRCP2,3
1Cardiology Department, James Cook
University Hospital, Middlesbrough, UK
2Cardiology Department, Freeman Hospital,
Newcastle upon Tyne, UK
3Institute of Cellular Medicine, Newcastle
University, Newcastle upon Tyne, UK
Correspondence
Azfar G. Zaman, Consultant Cardiologist,
Freeman Hospital, Newcastle Upon Tyne, NE7
7DN, UK.
Email: azfar.zaman@nuth.nhs.uk
Abstract
Objectives: We assessed the impact of diabetes mellitus (DM) on mortality after
percutaneous coronary intervention (PCI) for left main stem (LMS) disease. Second,
we compared mortality outcomes between non-insulin treated (NITDM) and insulin
treated diabetes (ITDM) in different clinical settings.
Background: There is a paucity of “real world” outcomes data in diabetic patients
undergoing LMS PCI.
Methods: We undertook a retrospective analysis of consecutive patients undergoing
unprotected LMS PCI at 2 high volume tertiary centers. Diabetic status and clinical
setting for PCI were recorded. The primary outcome measure was all-cause 30-day
and long-term mortality (up to 36 months) post index PCI.
Results: Between 2003 and 2017, 2,675 patients undergoing index LMS PCI were
analyzed. Of those, 77.1% were non-DM, 15.8% NITDM, and 7.1% ITDM. Overall,
DM status was not associated with higher 30-day mortality (OR 1.39, 95% CI
0.89–2.16, p = .15). During a median follow-up of 36 months, there was a borderline
statistical association of DM with long-term mortality in all PCI settings (HR 1.31,
95% CI 1.00–1.71, p = .05). Compared to non-DM, ITDM but not NITDM was associ-
ated with short- and long-term mortality in all clinical presentations.
Conclusions: Overall, DM did not impact on 30-day mortality and had only a border-
line statistical association with long-term mortality. It did not have an influence on
mortality in non-emergency LMS PCI. The impact of DM on mortality outcomes
following LMS PCI was only significant in the insulin treated patients.
K E YWORD S
diabetes mellitus, left Main Coronary Disease, percutaneous Coronary Intervention
1 | INTRODUCTION
Diabetes mellitus (DM) is a recognized predictor of adverse outcomes in
patients with coronary artery disease (CAD). Patients with DM have
more extensive and complex CAD and have worse outcomes after
Abbreviations: CABG, coronary artery bypass graft; CAD, coronary artery disease; CS,
cardiogenic shock; DM, diabetes mellitus; ITDM, insulin treated diabetes mellitus; LMS, left
main stem; MVD, multivessel disease; NSTE-ACS, non-ST-elevation acute coronary
syndrome; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial
infarction.
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percutaneous coronary intervention (PCI).1 Revascularisation guidelines
for diabetic patients favor CABG in the setting of multivessel disease and
left main stem (LMS) disease.2 However, dedicated randomized trials in
diabetic patients comparing CABG versus PCI have tended to exclude
LMS disease3,4 and therefore, outcomes data for LMS PCI is lacking.
LMS PCI poses challenges, which are amplified by the presence of
DM. Approximately 80% of LMS disease involves the bifurcation, which
is associated with a higher risk of restenosis. DM is itself associated
with an increased risk of in-stent restenosis due to increased neointimal
and smooth muscle cell proliferation.5 Furthermore, patients with DM
have increased thrombus burden, which is more resistant to standard
antithrombotic therapy.6 The presence of DM is associated with stent
thrombosis,7 that in the setting of LMS, is likely to be fatal.
Current advances such as contemporary drug eluting stents,
improved intravascular imaging, and potent antiplatelet agents, have
improved outcomes after PCI, which is now an established safe and
effective option for LMS disease.8 The EXCEL trial added credence to
the existing revascularization guidelines, which support equipoise
between LMS PCI and CABG in low to intermediate anatomical
complexity.9 The trial demonstrated noninferiority of contemporary
PCI against CABG with respect to the composite end point of death,
stroke, or myocardial infarction (MI) for 3 years. Interestingly, the rela-
tive treatment effect for the primary endpoint was not affected by
DM status, a prespecified subgroup.10
There is paucity of “real world” long-term (beyond 12 months) out-
comes data in diabetic patients undergoing LMS PCI.11 Our study aim
was to assess and to compare mortality outcomes following LMS PCI in
patients with diabetes versus those without. A secondary aim was to
assess mortality in groups stratified according to insulin requirement
and to assess the clinical setting of the revascularization procedure.
2 | METHODS
2.1 | Study population
All consecutive patients undergoing unprotected LMS PCI between
January 21, 2003 and December 29, 2017 at two high volume
TABLE 1 Baseline clinical and
procedure characteristics according to
diabetic status
Non-DM (n = 2063) DM (n = 612) p value
Age, mean 68.3 70.3 <.001
Male, n (%) 1,489 (72.2) 420 (68.6) .088
BMI, mean 27.3 30.2 <.001
Risk factors
Hypertension, n (%) 1,205 (59.7) 492 (81.2) <.001
Hypercholesterolemia, n (%) 1,003 (49.6) 400 (66.1) <.001
Family history, n (%) 944 (49.9) 289 (52.6) .253
PVD, n (%) 179 (8.9) 104 (17.2) <.001
Current smoking, n (%) 390 (20.1) 88 (15.4) .003
Past medical history
Previous MI, n (%) 636 (31.2) 266 (43.8) <.001
Previous PCI, n (%) 360 (17.6) 158 (26.1) <.001
Previous CABG, n (%) 74 (3.6) 53 (8.7) <.001
CVD, n (%) 156 (7.7) 62 (10.2) .049
Severe renal disease, n (%) 69 (3.4) 58 (9.5) <.001
Clinical setting
Elective, n (%) 651 (31.6) 184 (30.1) .485
Urgent, n (%) 1,012 (49.1) 338 (55.2) .007
Emergency, n (%) 400 (19.4) 90 (14.7) .009
Procedure details
Radial access, n (%) 1,361 (66.0) 406 (66.3) .866
Intravascular imaging, n (%) 595 (28.8) 179 (29.2) .845
MVD, n (%) 82.9 (1709) 91.0 (557) <.001
MVPCI, n (%) 1,288 (63.0) 411 (67.3) .056
Stents, n (%) 2020 (97.9) 599 (97.9) .952
DES, n (%) 1,768 (85.7) 535 (87.4) .281
Cardiogenic shock, n (%) 169 (8.2) 73 (11.9) .005
Abbreviations: BMI, body mass index; CVD, cerebrovascular disease; DES, drug eluting stents; DM,
diabetes mellitus; MVD, multivessel disease; MVPCI, multivessel PCI; PVD, peripheral vascular disease.
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(combined >5,000 PCI procedures/year) tertiary centers in the North
East of England were included. The Freeman Hospital, Newcastle
Upon Tyne and James Cook University Hospital, Middlesbrough serve
a population of >3 million with patients referred from the local area
and 12 surrounding district general hospitals.
2.2 | Data collection and study design
Baseline demographics, clinical presentation, and procedure details
are prospectively entered into a dedicated PCI database. Data defini-
tions are consistent across both sites and adhere to the National Insti-
tute for Cardiovascular Outcomes (NICOR)/British Cardiovascular
Intervention Society (BCIS) standard dataset. Data are used for sub-
mission to national audit and for quality purposes, including public
reporting of the results. Research departments are permitted to use
anonymised data for secondary analysis purposes. Mortality data were
provided by the Office of National Statistics (ONS) and are routinely
linked to the database using NHS patient-unique identification
numbers.
The database was retrospectively interrogated for PCI where at
least one vessel treated was the LMS. Only index cases during the
defined time period were included in the analysis. PCI to ostial left
anterior descending (LAD) and/or left circumflex disease with stenting
back to LMS were included. Protected LMS PCI and PCI for LMS iat-
rogenic dissection were excluded. Diabetic status was recorded as
nonDM, non-insulin treated DM (NITDM) or insulin treated DM
(ITDM). The clinical setting for PCI was recorded as “elective” for
patients presenting with stable angina, “urgent” for patients with non-
ST-elevation acute coronary syndrome (NSTE-ACS), and “emergency”
for patients with ST-elevation myocardial infarction (STEMI).
2.3 | Outcome measures
The primary outcome measure was all-cause mortality assessed at
two time points: 30-days and long-term (up to 36 months) post index
PCI. Mortality was assessed up to October 1, 2018 and patient
follow-up was censored at this time point or upon death.
2.4 | Statistical analysis
Data are presented as percentages for categorical variables and as
means ±SD or medians and interquartile ranges (25th– 75th) for
continuous variables. Comparisons between groups were made using
chi-square test for categorical variables and one-way ANOVA for con-
tinuous variables.
Multiple logistic regression was used to test the impact of DM
status on 30-day mortality and adjust for the following confounders
selected as per clinical consensus: age, gender, peripheral vascular
disease (PVD), previous MI, previous PCI, previous CABG, severe
renal disease (defined as Cr 200 μmol/L or dialysis), multivessel
TABLE 2 Types of stents used
Non-DM NITDM ITDM
Bare metal stents,
n (%)
256 (12.6) 50 (12.0) 15 (8.1)
First generation stents,
n (%)
201 (9.9) 27 (6.5) 24 (13.0)
Newer generation stents,
n (%)
1,567 (77.4) 339 (81.5) 145 (78.8)
Note: First generation stents were Taxus (Boston Scientific) and Cypher
(Cordis Corp.) stents. Newer generation stents were mainly Xience
(Abbott Vascular), Promus (Boston Scientific), and Resolute Onyx
(Medtronic) stents.
Abbreviations: DM, diabetes mellitus; ITDM, insulin treated diabetes
mellitus; NITDM, non-insulin treated diabetes mellitus.
TABLE 3 Logistics regression analysis for 30-day mortality in all
left main stem (LMS) percutaneous coronary intervention (PCI) cases
Odds
ratio
95% confidence
interval
p
value
Age 1.04 1.02–1.06 <.001
Male 0.82 0.52–1.29 .39
PVD 1.33 0.77–2.29 .30
Prev MI 1.06 0.68–1.66 .80
Prev PCI 0.57 0.31–1.04 .07
Prev CABG 0.72 0.28–1.89 .51
Renal disease 3.05 1.65–5.63 <.001
Multivessel
disease
4.23 1.29–13.90 .02
Diabetes 1.39 0.89–2.16 .15
Femoral access 1.95 1.28–2.95 .002
Multivessel PCI 1.20 0.76–1.89 .43
Abbreviations: CABG, coronary artery bypass graft; MI, myocardial
infarction; PCI, percutaneous coronary intervention; PVD, peripheral
vascular disease.
F IGURE 1 Thirty-day mortality according to diabetes subgroups
and clinical settings in noncardiogenic shock (CS) patients [Color
figure can be viewed at wileyonlinelibrary.com]
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disease defined as two or more vessel disease with >50% stenosis,
multivessel PCI defined as PCI to two or more vessels and diabetes
group. Cardiogenic shock (CS) was excluded in the Kaplan–Meier and
sensitivity analyzes due to its overbearing impact on mortality. Good-
ness of fit for the logistic regression model was assessed using the
Hosmer–Lemeshow test and model discrimination by the C-statistic.
Kaplan–Meier survival curves were generated, and the log-rank test
was used to assess differences in survival for unadjusted data. Cox
proportional hazards regression was used to assess impact of diabetes
groups on longer-term mortality following adjustment for aforemen-
tioned confounders. A p value of less than .05 was considered to indi-
cate statistical significance.
TABLE 4 Odds ratio for 30-day mortality according to diabetic subtype (compared to non-diabetic) stratified to clinical setting
Adjusted OR (95% CI)
DM NITDM ITDM
All cases 1.39 (0.89–2.16) 0.98 (0.56–1.73) 2.38 (1.29–4.38)
Urgent 1.11 (0.58–2.11) 0.79 (0.34–1.83) 1.80 (0.75–4.29)
Emergency 4.27 (1.84–9.88) 3.20 (1.21–8.46) 6.09 (1.73–21.41)
Abbreviations: DM, diabetes mellitus; ITDM, insulin treated diabetes mellitus; NITDM, non-insulin treated diabetes mellitus.
F IGURE 2 Kaplan–Meier curves demonstrating differential mortality according to diabetes mellitus (DM) status (a) DM subtype (b) in all
percutaneous coronary intervention (PCI) cases and (c) in urgent cases [Color figure can be viewed at wileyonlinelibrary.com]
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3 | RESULTS
3.1 | Study groups, baseline and procedure
characteristics
A total of 2,702 patients underwent 2,778 unprotected LMS PCI
during the study period. Seventy-six patients underwent repeat inter-
ventions to the LMS; only the index procedures were included.
Twenty-seven patients were excluded, as their diabetic status was not
recorded. Of the remaining 2,675 patients, 2063 (77.1%) were non-
DM, 422 (15.8%) NITDM, and 190 (7.1%) ITDM.
Table 1 shows the baseline clinical and procedural character-
istics according to the diabetic status. Differences between
non-DM, NITDM, and ITDM are shown in Table A in Appendix
section. Patients with DM had a higher burden of cardiovascular
risk factors, previous MI, and prior revascularization. This group
was also characterized by higher risk PCI features including
severe renal disease, multivessel (MVD) disease, and CS. Half
of the cases were urgent PCI for NSTE-ACS. We found no signifi-
cant difference in intravascular imaging use between DM and
non-DM. The majority of patients received newer generation
stents (Table 2).
3.2 | Thirty-day mortality
Overall 30-day mortality was 209/2675 (7.8%). Mortality in patients
with and without CS was 93/242 (38.4%) and 116/2433 (4.8%),
respectively. Figure 1 demonstrates 30-day mortality according to dia-
betes subgroups and clinical indications in non-CS patients. Mortality
was highest in ITDM undergoing emergency PCI. In a logistic regres-
sion model including all LMS PCI excluding CS cases, DM status was
not associated with 30-day mortality (OR 1.39, 95% CI, p = .15). The
following were independent predictors: age, renal disease, MVD, and
femoral access (Table 3). The logistic model showed good discrimina-
tion and fit (C-statistic 0.72, Hosmer–Lemeshow p value = .575).
When analyzing DM subgroups, ITDM was significantly associated
with 30-day mortality in all settings (Table 4). ITDM and NITDM
showed significant associations in the emergency but not the urgent
setting. Regression analyzes were not performed in the stable angina
group due to low event rates.
3.3 | Long-term mortality
During a median follow-up of 36 months, Kaplan–Meier curves
demonstrate that patients with DM had higher mortality than non-
DM (Log Rank test p = .001, Figure 2a). Compared to non-DM,
patients with NITDM had similar mortality (p = .052) while patients
with ITDM had significantly higher mortality (p < .001) (Figure 2b).
A similar pattern was observed in patients undergoing urgent
PCI, the largest group studied (Figure 2c). Cox regression analysis
showed that there was a borderline statistical association of DM
with long-term mortality in all PCI settings (HR 1.31, 95% CI
1.00–1.71, p = .05). Other independent predictors were age, PVD,
previous MI, renal impairment, MVD, and femoral access (Table 5).
Compared to non-DM, ITDM but not NITDM was associated with
long-term mortality in all PCI cases (Table 6). All DM subtypes were
significant predictors of poor outcome in PPCI to LMS in STEMI.
The impact of DM on long-term mortality was not significant when
stratified to 3 “PCI eras” (2003–2007, 2008–2012, 2013–2017)
(Table B in Appendix).
TABLE 6 Hazards ratio for long-term mortality according to diabetic sub-type (compared to non-diabetic) stratified to clinical setting
Adjusted HR (95% CI)
DM NITDM ITDM
All cases 1.31 (1.00–1.71) 1.21 (0.89–1.66) 1.54 (1.02–2.31)
Elective 1.75 (0.90–3.39) 1.91 (0.95–3.82) 1.25 (0.35–4.40)
Urgent 1.05 (0.74–1.50) 0.91 (0.59–1.41) 1.35 (0.81–2.24)
Emergency 2.29 (1.30–4.01) 2.14 (1.13–4.05) 2.69 (1.12–6.44)
Abbreviations: DM, diabetes mellitus; ITDM, insulin treated diabetes mellitus; NITDM, non-insulin treated diabetes mellitus.
TABLE 5 Cox regression analysis for 3-year mortality in all PCI
cases
Hazards
ratio
95% confidence
interval
p
value
Age 1.03 1.02–1.04 <.001
Male 0.84 0.64–1.11 .84
PVD 1.56 1.14–2.13 .005
Prev MI 1.85 1.42–2.40 <.001
Prev PCI 0.56 0.39–0.78 <.001
Prev CABG 0.57 0.32–1.04 .07
Renal disease 2.93 2.05–4.20 <.001
Multivessel
disease
1.80 1.10–2.95 .02
Diabetes 1.31 1.00–1.71 .05
Femoral access 1.53 1.19–1.97 .001
Multivessel PCI 0.91 0.70–1.18 .47
Abbreviations: CABG, coronary artery bypass graft; MI, myocardial
infarction; PCI, percutaneous coronary intervention; PVD, peripheral
vascular disease.
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4 | DISCUSSION
Our analysis of patients treated with LMS PCI showed that DM status
was not an independent predictor of 30-day in the non-emergency
setting. It had only a borderline statistical association with long-term
mortality.
When considering DM subtypes, ITDM but not NITDM was asso-
ciated with mortality, with the greatest impact in the emergency
setting—a finding reported previously in a large series of patients
undergoing PCI to any vessel.12 We can speculate that the higher bur-
den of cardiovascular risk factors such as PVD and renal disease, mul-
tivessel disease and low usage of radial access may have contributed
to the increased mortality seen in the ITDM group.
Previous studies have shown that DM adversely affects outcomes
following PCI.13,14 However, our study showed a differential impact
on mortality dependent on DM type. This may be the result
of significant improvement in risk factor control, leading to the reduc-
tion of CAD risk in diabetes.15 The rates of diabetes-related
macrovascular complications have also reduced significantly in the
past two decades.16 Secondary preventative strategies continue to
evolve with SGLT2 inhibitors demonstrating a significant reduction in
major adverse cardiac events in Type 2 DM with established CAD.17
Left main stem disease is associated with significant myocardial
jeopardy and CABG has historically been the preferred revasculariza-
tion modality. In diabetic patients requiring revascularization, CABG
with an internal mammary graft to the left anterior descending artery,
has been associated with lower mortality compared with PCI in the
setting of complex multivessel disease in randomized controlled tri-
als.4,18 Current guidelines recommend CABG as the standard of care
for diabetic patients with CAD of intermediate to high SYNTAX
scores including in the setting of LMS disease.2 However, DM was
not an independent predictor of events once the SYNTAX score was
entered in the multivariable model.19 Consequently, DM is excluded
in the SYNTAX 2 score that helps determine the preferred revasculari-
zation strategy.20 In a pooled analysis of three randomized trials com-
paring CABG versus PCI in patients with DM and low or intermediate
anatomic complexity (SYNTAX less or equal to 32), both groups had
similar 5-year rates of all-cause death, cardiac death, and the compos-
ite of death, MI, or stroke.21
With contemporary interventional technology, there is increasing
evidence that LMS PCI is a comparatively effective and safe strategy.
A prespecified subgroup analysis of the EXCEL trial10 reported rates
of a 3-year primary endpoint to be similar after treatment with PCI
and CABG in diabetic (20.7% vs. 19.3%) and in non-diabetic patients
(12.9% vs. 12.9%). Importantly, DM status showed no significant
interaction effect with CABG and PCI in establishing short- and long-
term outcomes suggesting that DM status is not a critical determinant
of the mode of revascularization strategy in LMS disease.
In our study, DM status, as a dichotomous variable, did not impact
on early or late mortality. The morbidity associated with DM such
as PVD, MVD, and renal disease were independent predictors of
mortality. Increasing evidence suggesting that the presence of
DM should not be a factor in determining revascularization strategy
(PCI vs. CABG) for LMS disease, which is supported by data from our
study. In the absence of significant vascular complications, diabetic
patients on diet or oral hypoglycemic have similar outcomes to non-
diabetic patients. However, in patients on insulin treatment, there is
an increased mortality risk especially after ST-elevation MI.
5 | LIMITATIONS
Our primary data source is the BCIS database. While data are entered
prospectively and audited, it does not capture all the clinical variables
that can impact on prognosis. We do not have information about sig-
nificant non cardiac comorbidities. Left ventricular function was
recorded in less than 40% patients and therefore was missing from
analysis. A comprehensive anatomical evaluation is not available and
SYNTAX score is not routinely documented. We have defined MVD
as a minimum of two non-LMS epicardial coronary stenoses >50% in
an attempt to differentiate isolated LMS disease (LMS shaft or bifur-
cation) against LMS disease with more complex disease pattern. Our
data shows that MVD is an important predictor of mortality. In our
institutions, patients with nonemergency presentations and significant
LMS disease are discussed in a heart team. Our database captures a
heterogeneous group of patients undergoing LMS PCI after clinical
presentation, co-morbidities, anatomical complexity, and patient pref-
erence have all been considered. We do not have information about
medical therapy following PCI. In both centers, the following dual
antiplatelet guidelines are practiced: in addition to long-term aspirin,
elective patients receive 12 months of clopidogrel; NSTE-ACS,
12 months of ticagrelor and STEMI, 12 months of ticagrelor or pra-
sugrel. Of note, prasugrel and ticagrelor were in use after 2009.
Finally, we do not have follow-up data for MI and repeat revasculari-
zation or outcomes beyond 3 years.
6 | CONCLUSIONS
Our data in a large real-world cohort of patients showed that DM did
not impact on 30-day mortality and had only a borderline statistical
association with long-term mortality over a 3 year follow-up period. It
did not have an influence on mortality in non-emergency LMS PCI.
This is in accordance with the contemporary evidence from clinical tri-
als of LMS PCI showing equipoise between percutaneous and surgical
revascularization strategies. We also showed that non-insulin treated
DM did not affect short- and long-term mortality when adjusted for
other confounders. A consistent finding from other studies was also
replicated in this registry and confirmed that increased mortality fol-
lowing LMS PCI in DM patients was only present in insulin treated
patients. Our data provides both, a cautionary note for LMS PCI in the
insulin treated patients and evidence for future studies to focus on
these patients.
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